Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 70: Issue 2
Frequency of mutations in erm(39) related to clarithromycin resistance and in rrl related to linezolid resistance in clinical isolates of Mycobacterium fortuitum in Iran
Authors:
Mohammad Hashemzadeh Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Search for other papers by Mohammad Hashemzadeh in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0001-5410-2561
,
Aram Asareh Zadegan Dezfuli Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Search for other papers by Aram Asareh Zadegan Dezfuli in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0003-3947-146X
,
Azar Dokht Khosravi Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Search for other papers by Azar Dokht Khosravi in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0002-7852-6868
,
Nazanin Ahmad Khosravi Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Search for other papers by Nazanin Ahmad Khosravi in
Current site
Google Scholar
PubMed Close
, and
Abdorazagh Hashemi Shahraki Division of Pulmonary, Critical Care and Sleep, College of Medicine-Jacksonville, University of Florida, 655 West 11th Street, Jacksonville, FL, 32209, USA

Search for other papers by Abdorazagh Hashemi Shahraki in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0003-1852-194X
Pages:
167–176
Online Publication Date:
24 May 2023
Publication Date:
16 Jun 2023
Article Category:
Research Article
DOI:
https://doi.org/10.1556/030.2023.02020
Keywords:
non-tuberculous mycobacteria; Mycobacterium fortuitum; clarithromycin; linezolid; drug resistance
Restricted access
Get Permissions

Abstract

Mycobacterium fortuitum is a clinically important species among nontuberculous mycobacteria (NTM). Treatment of diseases caused by NTM is challenging. The aim of this study was identification of drug susceptibility and detection of mutations in erm(39) related to clarithromycin resistance and in rrl related to linezolid resistance in clinical isolates of M. fortuitum in Iran. In the study, 328 clinical NTM isolates were subjected to identification based on rpoB and 15% of isolates were assigned to M. fortuitum. Minimum inhibitory concentration for clarithromycin and linezolid was determined by E-test. Altogether 64% of M. fortuitum isolates showed resistanc to clarithromycin and 18% of M. fortuitum isolates showed resistance to linezolid. PCR and DNA sequencing were performed in erm(39) and in rrl genes for detection of mutations related to clarithromycin and linezolid resistance, respectively. Sequencing analysis revealed (84.37%) single nucleotide polymorphisms in the erm(39). A total 55.55% of M. fortuitum isolates harbored an A→G, 14.81% harbored an C→A, 29.62% harbored an G→T mutation in erm(39) at position 124, 135, 275. Seven strains harbored point mutation in the rrl gene either at T2131C or at A2358G. Our findings showed M. fortuitum isolates have become a serious problem with high-level antibiotic resistance. The existence of drug resistance to clarithromycin and linezolid indicates more attention to the study of drug resistance in M. fortuitum.

  • 1.

    Muñoz-Egea MC, Akir A, Esteban J. Mycobacterium biofilms. Biofilm 2023; 5: 100107. https://doi.org/10.1016/j.bioflm.2023.100107.

  • 2.

    Hashemzadeh M, Dezfuli AA, Khosravi AD, Bandbal MM, Ghorbani A, Hamed M, Dezfuli SK. Molecular identification of non-tuberculous mycobacterial species isolated from extrapulmonary samples using real-time PCR and rpoB sequence analysis. AMB Express 2023; 13(1): 1–6. https://doi.org/10.1186/s13568-023-01553-8.

    • Search Google Scholar
    • Export Citation
  • 3.

    Koh, WJ, Jeong, BH, Kim, SY, Jeon, K, Park, KU, Jhun, BW, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 2017; 64: 309–316. https://doi.org/10.1093/cid/ciw724.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hashemi-Shahraki A, Darban Sarokhalil D, Heidarieh P, Feizabadi MM, Deshmir-Salameh S, Khazaee S, et al. Mycobacterium simiae, a possible emerging pathogen in Iran. Jpn J Infect Dis 2013; 66: 475-479. https://doi.org/10.7883/yoken.66.475.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55: 170–177. https://doi.org/10.1093/jac/dkh523.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Hashemi-Shahraki A, Bostanabad SZ, Heidarieh P, Titov LP, Khosravi AD, Sheikhi N, et al. Species spectrum of nontuberculous mycobacteria isolated from suspected tuberculosis patients, identification by multi locus sequence analysis. Infect Genet Evol 2013; 20: 312–324. https://doi.org/10.1016/j.meegid.2013.08.027.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Shojaei H, Heidarieh P, Hashemi A, Feizabadi MM, Naser AD. Species identification of neglected nontuberculous mycobacteria in a developing country. Jpn J Infect Dis 2011; 64: 265–271.

    • Search Google Scholar
    • Export Citation
  • 8.

    Tabarsi P, Baghaei P, Farnia P, Mansouri N, Chitsaz E, Sheikholeslam F, et al. Nontuberculous mycobacteria among patients who are suspected for multidrugresistant tuberculosis-need for earlier identification of nontuberculosis mycobacteria. Am J Med Sci 2009; 337: 182–184. https://doi.org/10.1097/maj.0b013e318185d32f.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Shahraki AH, Heidarieh P, Bostanabad SZ, Khosravi AD, Hashemzadeh M, Khandan S, et al. Multidrug-resistant tuberculosis may be nontuberculous mycobacteria. Eur J Intern Med 2015; 26: 279–284. https://doi.org/10.1016/j.ejim.2015.03.001.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15: 149-161. https://doi.org/10.1016/j.drup.2012.04.001.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther 2008; 28: 1134–1139. https://doi.org/10.1111/j.1365-2036.2008.03821.x.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Nie W, Duan H, Huang H, Lu Y, Chu N. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis Mycobacteria isolates. Biomed Res Int 2015; 2015: 506598. https://doi.org/10.1155/2015/506598.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Clinical and Laboratory Standards Institute, “Susceptibility testing of mycobacteria, norcardiae, and other aerobic actinomycetes; approved standard”, CLSI Document M24-A, CLSI, Wayne, Pa, USA, 2011.

    • Search Google Scholar
    • Export Citation
  • 14.

    Zhu YC, Mitchell KK, Nazarian EJ, Escuyer VE, Musser KA. Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus. Mol Cell Probes 2015; 29: 514–516. https://doi.org/10.1016/j.mcp.2015.08.007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Cowman S, Burns K, Benson S, Wilson R, Loebinger MR. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect 2016; 72: 324-331. https://doi.org/10.1016/j.jinf.2015.12.007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Wenjuan N, Hongfei D, Hairong H, Yu L, Naihui C. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis mycobacteria isolates. Biomed Res Int 2016; 2015: 506598. https://doi.org/10.1155/2015/506598.

    • Search Google Scholar
    • Export Citation
  • 17.

    Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, et al. Assessment of clarithromycin susceptibility in strains belonging tothe Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother.2011; 55: 775-781. https://doi.org/10.1128/AAC.00861-10.

    • Search Google Scholar
    • Export Citation
  • 18.

    Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P. Inducible and acquired clarithromycin resistance in the Mycobacterium abscessus complex. PLoS One 2015; 8: 10: e0140166. https://doi.org/10.1371/journal.pone.0140166.

    • Search Google Scholar
    • Export Citation
  • 19.

    Mahon CR, Lehman DC, Manuselis G Jr. Textbook of diagnostic microbiology. St. Louis, MI: Saunders; 2014.

  • 20.

    Adékambi T, Colson P, Drancourt M. rpoB-based identification of non-pigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003: 41, 5699–5708. https://doi.org/10.1128/JCM.41.12.5699-5708.2003.

    • Search Google Scholar
    • Export Citation
  • 21.

    Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016; 33: 1870–1874. https://doi.org/10.1093/molbev/msw054.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Radzniwan MR, Tohid H, Ahmad S, Mohd AF, Anshar FM. Isolation of Mycobacterium fortuitum in sputum specimens of a patient with chronic cough: is it clinically significant? Malays Fam Physician 2014; 9: 38.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Guo Q, Chu H, Ye M, Zhang Z, Li B, Yang S, et al. The clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. Antimicrob Agents Chemother 2018; 62: e02360–17. https://doi.org/10.1128/AAC.02360-17.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Liu H, Lian L, Jiang Y, Huang M, Tan Y, Zhao X, et al. Identification of species of nontuberculous mycobacteria clinical isolates from 8 provinces of China. Biomed Res Int 2016; 2: 2153910. https://doi.org/10.1155/2016/2153910.

    • Search Google Scholar
    • Export Citation
  • 25.

    Khosravi AD, Mirsaeidi M, Farahani A, Tabandeh MR, Mohajeri P, Shoja S, et al. Prevalence of nontuberculous mycobacteria and high efficacy of D-cycloserine and its synergistic effect with clarithromycin against Mycobacterium fortuitum and Mycobacterium abscessus. Infect Drug Resist 2018; 11: 2521. https://doi.org/10.2147/IDR.S187554.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Pereira AC, Ramos B, Reis AC, Cunha MV. Non-tuberculous mycobacteria: molecular and physiological bases of virulence and adaptation to ecological niches. Microorganisms 2020; 8:1380. https://doi.org/10.3390/microorganisms8091380.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Parvin H, Hasan S, Mohamad Mehdi F, Asghar H, Abodolrazagh H, Behrooz A, et al. Molecular identification and conventional susceptibility testing of iranian clinical mycobacterium fortuitum isolates 2010; 13: 210-215. http://ijbms.mums.ac.ir/article_5065.html.

    • Search Google Scholar
    • Export Citation
  • 28.

    Saxena S, Spaink HP, Forn-Cuní G. Drug. Resistance in nontuberculous mycobacteria: mechanisms and models. Biology 2021, 10:96. https://doi.org/10.3390/biology10020096.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kim BJ, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54: 347-353. https://doi.org/10.1111/j.1348-0421.2010.00221.x.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Leao SC, Tortoli E, Viana-Niero C, Ueki SY, Lima KV, Lopes ML, et al. Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol 2009; 47: 2691–2698. https://doi.org/10.1128/JCM.00808-09.

    • Search Google Scholar
    • Export Citation
  • 31.

    Mougari F, Bouziane F, Crockett F, Nessar R, Chau F, Veziris N, et al. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother 2017; 61: e00943–16. https://doi.org/10.1128/AAC.00943-16.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand
Cover Acta Microbiologica et Immunologica Hungarica
Acta Microbiologica et Immunologica Hungarica A Quarterly of the Hungarian Academy of Sciences
Print ISSN:
1217-8950
Online ISSN:
1588-2640

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2024  
Web of Science  
Journal Impact Factor 1.6
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.37
Rank by Journal Citation Indicator Q4 (Immunology)
Scopus  
CiteScore 2.8
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.45
Scimago  
SJR index 0.41
SJR Q rank Q3

 

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article (only for OA publications)
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation		 1954
Volumes
per Year		 1
Issues
per Year		 4
Founder Magyar Tudományos Akadémia
Founder's
Address		 H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2025 93 0 0
Feb 2025 139 0 0
Mar 2025 105 0 0
Apr 2025 56 0 0
May 2025 53 0 0
Jun 2025 50 0 0
Jul 2025 0 0 0